Neuroscience Research on Drug Abuse (R01)

The summary for the Neuroscience Research on Drug Abuse (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Neuroscience Research on Drug Abuse (R01): Substance abuse results in widespread changes in brain structure and function, and research is needed to explain these changes and how they affect behavior. The goals of the research areas described in this Neuroscience of Drug Abuse FOA are to understand the neurobiological mechanisms underlying drug abuse and addiction, with special emphasis on changes that occur during chronic drug use, withdrawal and relapse. An understanding of the basic mechanisms underlying drug addiction can help to identify targets for prevention and treatment interventions. Research utilizing basic, translational, or clinical approaches is appropriate.

Federal Grant Title:	Neuroscience Research on Drug Abuse (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-13-338
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	Jan 07, 2017
Original Application Deadline:	Jan 07, 2017
Posted Date:	Aug 26, 2013
Creation Date:	Aug 26, 2013
Archive Date:	Feb 07, 2017
Total Program Funding:
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Native American tribal governments (Federally recognized)
Others (see text field entitled "Additional Information on Eligibility" for clarification)
For profit organizations other than small businesses
County governments
Public housing authorities/Indian housing authorities
Small businesses
State governments
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
City or township governments
Special district governments
Independent school districts
Private institutions of higher education
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PA-13-338.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...